Table 4.

Monomorphic large cells with diffuse pattern

	CD20	CD79a	CD138	EBER
DLBCL	+	+	/+	−
Plasmablastic	−	−	+	+

+, >50%; –, >than 5%; −/+, 5–25%; +/− 25–50%; Caveat: CD20 may be negative in Rituximab treated DLBCL; CD79a positivity is confirmatory